Business Context and Reporting Period
This Form 8-K Current Report was filed by Amneal Pharmaceuticals, Inc. on December 15, 2023. The report details a corporate action regarding the transfer of the listing of the Company's Class A Common Stock (trading symbol: AMRX) from the New York Stock Exchange (NYSE) to The Nasdaq Stock Market LLC (Nasdaq).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the administrative transfer of the stock listing and does not contain financial performance data for the period.
Material Changes
- Listing Transfer: The Company notified the NYSE of its intention to voluntarily withdraw its listing and transfer to Nasdaq.
- Timeline: The NYSE listing is expected to end at market close on December 26, 2023, with the Nasdaq listing commencing at market open on December 27, 2023.
- Trading Symbol: The Common Stock will continue to trade under the symbol "AMRX" on Nasdaq.
Guidance, Outlook, and Risks
The filing includes a Regulation FD Disclosure (Item 7.01) referencing a press release attached as Exhibit 99.1. The document states that the information in this section and the attached exhibit is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific financial guidance, management commentary on future performance, or discussion of risks and contingencies is provided within the text of this 8-K.
Investor Verification Checklist
- Confirm the exact date and time of the trading transition from NYSE to Nasdaq (Dec 26 close to Dec 27 open).
- Verify that the trading symbol remains "AMRX" post-transfer.
- Review the attached Press Release (Exhibit 99.1) for any additional context regarding the strategic rationale for the listing transfer.
- Check subsequent filings for any financial updates, as this 8-K contains no financial metrics.